iwCAR-T 2022 | The future of CAR-T therapy in ALL
In this captivating discussion chaired by Noelle Frey, MD, MSCE, University of Pennsylvania, Philadelphia, PA, Bijal Shah, MD, MS, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, and Shannon Maude, MD, PhD, Children’s Hospital of Philadelphia, Philadelphia, PA, share their insights into the future of CAR-T therapy for acute lymphoblastic leukemia (ALL). They talk on the impact of the approval of tisagenlecleucel (tisa-cel) in adult patients, stressing the importance of finding strategies to improve the persistence and durability of responses to CAR-T therapy. They also comment on the advent of allogeneic CAR-Ts and highlight the advantages of humanized products, as well as the different strategies to manufacture dual targeting CAR-Ts. This discussion took place at the 4th International Workshop on CAR-T (iwCAR-T) 2022 held in Tampa, FL.
